1. Emanuelli A, Manikoth Ayyathan D, Koganti P, Shah P, Apel-Sarid L, Paolini B, Detroja R, Frenkel-Morgenstern M, Blank M. Altered expression and localization of tumor suppressive E3 ubiquitin ligase SMURF2 in human prostate and breast cancer. Cancers (Basel). 11(4): 556, 2019.


2. Koganti P, Levy-Cohen G, Blank M. Smurfs in protein homeostasis, signaling and cancer. Frontiers in Oncology. 8: 295, 2018. Invited Review


3. Blank M. Emerging roles of HECT type E3 ubiquitin ligase Smurf2 in cancer. ESMO Open. 3 (Suppl 2): A101, 2018.


4. Borroni AP, Emanuelli A, Shah PA, Ilić N, Apel-Sarid L, Paolini B,  Manikoth Ayyathan D, Koganti P, Levy-Cohen G, Blank M. Smurf2 regulates stability and the autophagic-lysosomal turnover of lamin A and its disease-associated form progerin. Aging Cell. 17(2), 2018.


5. Hausmann M, Ilic N,  Pilarczyk G, Lee J-H,  Logeswaran A, Borroni AP, Krufczik M, Theda F,  Waltrich N, Bestvater F, Hildenbrand G, Cremer C, Blank M. Challenges for super-resolution localization microscopy and biomolecular fluorescent nano-probing in cancer research. Int J Mol Sci. 18(10), 2066, 2017. 


6. Emanuelli A, Borroni AP, Apel-Sarid L, Shah PA, Manikoth Ayyathan D, Koganti P, Levy-Cohen G and Blank M. Smurf2-mediated stabilization of DNA topoisomerase IIα controls genomic integrity. Cancer Research. 77(16): 4217-4227, 2017. Cover Image


7. Manikoth Ayyathan D, Ilic N, Gil-Henn H and Blank M. Generation of SMURF2  knockout human cells using the CRISPR/Cas9 system. Analytical Biochemistry. 531: 56-59, 2017.


8. Blank M, Mandel M, Dror N, Solomon A, Barlya T and Lavie G. Hypericin targets multiple signaling mediators in cancer cells generating unique, anti-tumoral, anti-metastatic, and anti-angiogenic activities with evidence for clinical applicability. Medical Research Archives. 5(3): 1-30, 2017. DOI: 10.18103/mra.v5i3.881. Invited Review


9. Zou X and Blank M. Targeting p38 MAP kinase signaling in cancer through post-translational modifications. Cancer Letters. 384: 19-26, 2017.


10. Blank M. The role of E3 ubiquitin ligase Smurf2 in cancer. European Journal of Cancer. 61 (Suppl 1): S73, 2016.


11. Zou X, Levy-Cohen G and Blank M. MoIecular functions of NEDD4 E3 ubiquitin ligases in cancer. Biochimica et Biophysica Acta (BBA) - Rev Cancer. 1856: 91-106, 2015.


12. Levy-Cohen G and Blank M. Functional analysis of protein ubiquitination. Analytical Biochemistry. 484: 37-39, 2015.


13. Meir M, Galanty Y, Kashani L, Blank M, Fernández-Ávila MJ, Andres Cruz-Garcia A, Star A, Shochot L, Thomas Y, Garrett LJ, Chamovitz D, Bodine DM, Kurz T, Huertas P, Ziv Y, Shiloh Y. The COP9 signalosome is vital for timely repair of DNA double-strand breaks. Nucleic Acids Research. 43(9): 4517-4530, 2015.


14. Zhao X, Parpart S, Takai A, Roessler S, Budhu A, Yu Z, Blank M, Zhang YE, Jia HL,Ye QH, Qin LX, Tang ZY, Thorgeirsson SS, Wang XW. Integrative genomics identifies YY1AP1 as an oncogenic driver in EpCAM+ AFP+hepatocellular Carcinoma. Oncogene. 34(39): 5095-5104, 2015.


15. Blank M and Zhang YE. Smurf2 is a novel tumor suppressor gene that governs chromatin structure and genome integrity through RNF20. Cancer Research. 72 (8 Supplement): 2195, 2012.


16. Blank M, Tang Y, Yamashita M, Burkett SS, Cheng S, Zhang YE. A tumor suppressor function of Smurf2 associated with controlling chromatin landscape and genome stability through RNF20. Nature Medicine. 18(2): 227-234, 2012. (PDF) Cover Image


17. Lavie G, Barliya T, Mandel M, Blank M, Ron Y, Orenstein A, Livnat T, Friedman N, Weiner L, Sheves M, Weinberger D. "Competitive quenching": a mechanisms by which perihydroxylated perylenequinone photosensitizers can prevent adverse phototoxic damage caused by verteporfin during photodynamic therapy. Photochemistry & Photobiology. 83(5): 1270-1277, 2007.


18. Blank M and Shiloh Y. Programs for cell death: apoptosis is only one way to go. Cell Cycle. 6: 686-695, 2007. Invited Review


19. Blank M, Lerenthal Y ,Mittelman L, Shiloh Y. Condensin I recruitment and uneven chromatin condensation precede mitotic cell death in response to DNA damage. The Journal of Cell Biology. 174: 195-206, 2006.


20. Burov SV, Iablokova TV, Dorosh M, Shkarubskaia ZP, Blank M, Epshtein N, Fridkin M. Luliberin analogues exhibiting a cytotoxic effect on tumor cells in vitro. Bioorganicheskaya khimiya. 32: 459-66, 2006.


21. Hazan S, Lavie G, Blank M, Mandel M, Grunbaum A, Meruelo D, Solomon A. Anti-angiogenic activities of hypericin in vivo: Potential for opthalmologic applications. Angiogenesis. 8: 35-42, 2005.


22. Weinberger D, Ron Y, Lusky M, Gaaton D, Orenstein A, Blank M, Mandel M, Livnat T, Barliya T, Lavie G. Competitive quenching: a possible novel approach in protecting RPE cells from damage during PDT. Current Eye Research. 30: 269-277, 2005.


23. Blank M, Lavie, G, Mandel M, Hazan S, Orenstein A, Keisari Y. Antimetastatic activity of the photodynamic agent hypericin in the dark. International Journal of Cancer. 111: 596-603, 2004. Cover Image


24. Blank M, Mandel M, Keisari Y, Meruelo D, Lavie G. Enhanced Hsp90 ubiquitinylation as a potential mechanism for mitotic cell death in cancer cells induced with hypericin. Cancer Research. 63: 8241-8247, 2003.


25. Blank M, Kostenich G, Kimel S, Lavie G, Keisari Y, Orenstein A. Wavelength Dependent Properties of Photodynamic Therapy Using Hypericin in vitro and in an Animal Model. Photochemistry & Photobiology. 76: 335-340, 2002.


26. Blank M, Mandel M, Hazan S, Keisari Y, Lavie G. Anti-cancer activities of hypericin in the dark. Photochemistry & Photobiology. 74: 120-125, 2001.


27. Blank M, Lavie G, Mandel M, Keisari Y. Effects of photodynamic therapy with hypericin in mice bearing highly invasive solid tumors. Oncology Research. 12: 409-418, 2001.